Synopsys Inc’s Post

A question rewired your brain about AI. We once asked ChatGPT, an icon of AI, the following question and it's answer was: "Yes, but with low probability." This is a paradox and dangerous feature in data analytics for decision making support. "Will AI replace and terminate the University of Cambridge?" Do you or any of your contacts need my expertise and my IP? We're selling, NOT talking. Thanks. Here is our pitch deck: "With our intellectual property (IP), a copyrighted multilingual metadata, we can do what ChatGPT, an icon of AI, can't do in data analytics. Without metadata, NO data can be found/retrieved, even by the most advanced technologies, like AI, supercomputers, etc. https://lnkd.in/g-aJFnXR Our IP can also make your information service UNIQUE in the world" P.S. We wrote this statement myself, without using any AI tool.

Intel® RealSense™ ID for Facial Authentication can unlock your door as well.

🚀 New Video Alert! Elevate your SoC design skills with the second episode of our SoC Design Series! In this video, we dive into a practical demo using the Corsair tool to design an AXI-Lite IP (Adder). Watch as we explore advanced register management techniques that streamline your SoC development process. Perfect for those looking to enhance their expertise in embedded systems and VLSI design! #SoCDesign #CorsairTool #AXILite #EmbeddedSystems #VLSIDesign #HardwareFirmware #TechEducation

Exciting Collaboration Alert in TechBio! 🧬💻 Recursion Pharmaceuticals, a trailblazer in AI-driven drug discovery, has announced last July 2023 a groundbreaking collaboration with NVIDIA, a leader in accelerated computing. This partnership is not just a leap forward for both companies but a significant milestone in the field of biotechnology & AI. Adding to that partnership, NVIDIA just announced at the JPM24 yesterday 8th of January that Amgen’s deCode will joined the party to form a powerful trio. 🔍 Key Highlights: • NVIDIA’s hefty $50 million investment in Recursion reflects the immense potential of this collaboration. • The partnership is focused on accelerating the development of AI foundation models for biology and chemistry, utilizing Recursion’s massive proprietary dataset, which surpasses 23 petabytes and encompasses over 3 trillion searchable gene & compound relationships. • NVIDIA’s BioNeMo cloud service for generative AI in drug discovery will play a critical role, providing tools to customize & deploy state-of-the-art biomolecular models at scale. • This collaboration is expected to democratize access to large-scale models in drug discovery, potentially revolutionizing the way new medicines are discovered & developed. Chris Gibson, Ph.D., Co-founder, & CEO of Recursion, & Jensen Huang, founder & CEO of NVIDIA, both emphasize the transformative impact of this alliance. It’s not just about bringing two powerhouses together but about solving one of humanity’s most challenging problems: efficient & effective drug discovery. 🌐 What This Means for the Industry: • Speeding up the drug discovery process, potentially saving years of research & millions of dollars. • Making advanced AI and machine learning tools more accessible to the broader biotech & pharmaceutical industry. • Fostering innovation in drug development with the fusion of digital biology, chemistry, & advanced AI software. 🤝 A New Era in Drug Discovery: This collaboration is a testament to the incredible synergies possible when tech and biotech converge. It’s a glimpse into a future where AI and ML are integral to uncovering new treatments and cures for complex diseases. 💡 Thoughts to Consider: • How will this partnership shape the future of drug discovery? • What implications does it have for personalized medicine and patient treatment? • How can other tech and biotech companies leverage such collaborations? David A. Sinclair A.O., Ph.D. , Aubrey de Grey , Chris Gibson & Jensen Huang 👉 any future collaboration ? 🔗 https://lnkd.in/ey97zqh4 https://lnkd.in/ebMqRrbK https://lnkd.in/eE5qvxUe #RecursionPharmaceuticals #NVIDIA #TechBio #DrugDiscovery #AIinHealthcare #Innovation #Biotechnology

The Olympic Games in Paris marks the 2nd time that OBS are deploying the completely software based "virtualized OB" concept where Intel COTS FPGA Programmable Acceleration Cards are used to "..accelerate encoding and transcoding where low latency and deterministic performance are necessary." This whitepaper from Intel provides an overview of the vOB solution and its benefits. I wonder what software they are running on the FPGA acceleration cards to make all this magic happen....? 🤔 #paris2024 #manifoldCLOUD

Our CEO, Sassine Ghazi, recently joined Daniel Newman's webcast to discuss his priorities for the company and the essential role Synopsys plays in customer R&D from silicon to systems. Watch a highlight below and the full conversation here: bit.ly/3O9q0rz

Learn more about Intel's announcements from #MWC24. #IAmIntel

Learn more about Intel's announcements from #MWC24. #IAmIntel

Learn more about Intel's announcements from #MWC24. #IAmIntel

Learn more about Intel's announcements from #MWC24. #IAmIntel